246 related articles for article (PubMed ID: 6083507)
21. [Usefulness of determining hepatic clearance of Tc-HEPIDA in the diagnosis and differential diagnosis of chronic diseases of the liver parenchyma].
Kuydowicz J; Studniarek M; Wojciechowski A; Liniecki J
Pol Tyg Lek; 1989 Apr 10-17; 44(15-16):358-60. PubMed ID: 2626353
[No Abstract] [Full Text] [Related]
22. Changes in antipyrine clearance and platelet count, but not conventional liver tests, correlate with fibrotic change in chronic hepatitis C: value for predicting fibrotic progression.
Coverdale SA; Samarasinghe DA; Lin R; Kench J; Byth K; Khan MH; Crewe E; Liddle C; George J; Farrell GC
Am J Gastroenterol; 2003 Jun; 98(6):1384-90. PubMed ID: 12818285
[TBL] [Abstract][Full Text] [Related]
23. Impaired ability of neutrophils to produce oxygen-derived free radicals in patients with chronic liver disease and hepatocellular carcinoma.
Uehara M; Sato N
Hepatology; 1994 Aug; 20(2):326-30. PubMed ID: 8045492
[TBL] [Abstract][Full Text] [Related]
24. Alpha-SMA expression in hepatic stellate cells and quantitative analysis of hepatic fibrosis in cirrhosis and in recurrent chronic hepatitis after liver transplantation.
Carpino G; Morini S; Ginanni Corradini S; Franchitto A; Merli M; Siciliano M; Gentili F; Onetti Muda A; Berloco P; Rossi M; Attili AF; Gaudio E
Dig Liver Dis; 2005 May; 37(5):349-56. PubMed ID: 15843085
[TBL] [Abstract][Full Text] [Related]
25. The effects of acute infectious hepatitis and cirrhosis of the liver on the nonerythropoietic component of early bilirubin.
Tarao K; Fukushima K; Endo O; Kamiyo A
J Lab Clin Med; 1976 Feb; 87(2):240-50. PubMed ID: 1245790
[TBL] [Abstract][Full Text] [Related]
26. Simple blood tests can predict compensated liver cirrhosis in patients with chronic hepatitis C.
Luo JC; Hwang SJ; Chang FY; Chu CW; Lai CR; Wang YJ; Lee PC; Tsay SH; Lee SD
Hepatogastroenterology; 2002; 49(44):478-81. PubMed ID: 11995477
[TBL] [Abstract][Full Text] [Related]
27. Impaired elimination of meperidine in patients with liver disease.
McHorse TS; Klotz U; Wilkinson G; Schenker S
Trans Assoc Am Physicians; 1974; 87():281-7. PubMed ID: 4456737
[No Abstract] [Full Text] [Related]
28. Colchicine clearance is impaired in alcoholic cirrhosis.
Leighton JA; Bay MK; Maldonado AL; Schenker S; Speeg KV
Hepatology; 1991 Dec; 14(6):1013-5. PubMed ID: 1959847
[TBL] [Abstract][Full Text] [Related]
29. Antipyrine clearance in comparison to conventional liver function tests in hepatitis C virus patients.
Mahmoud M; Abdel-Kader R; Hassanein M; Saleh S; Botros S
Eur J Pharmacol; 2007 Aug; 569(3):222-7. PubMed ID: 17628532
[TBL] [Abstract][Full Text] [Related]
30. Enhanced renal clearance of uric acid in hepatic cirrhosis.
Higuchi T; Nakamura T; Uchino H
Isr J Med Sci; 1981 Nov; 17(11):1015-8. PubMed ID: 7319788
[TBL] [Abstract][Full Text] [Related]
31. Serum leptin levels in patients with nonalcoholic chronic liver disease.
Nakamuta M; Tada S; Uchimura K; Enjoji M; Kinukawa N; Iwamoto H; Sugimoto R; Shimada M; Ohashi M; Sugimachi K; Nawata H
Hepatogastroenterology; 2001; 48(38):527-32. PubMed ID: 11379347
[TBL] [Abstract][Full Text] [Related]
32. Activity of chronic hepatitis. Correlation of clinical, biochemical and histological parameters in 32 cases.
Gayotto LC; Strauss E; Alves VA; da Silva LC
Rev Inst Med Trop Sao Paulo; 1983; 25(6):288-93. PubMed ID: 6200913
[No Abstract] [Full Text] [Related]
33. [Immunoelectrophoretic analysis of serum gamma globulins in chronic hepatitis and hepatic cirrhosis].
Ciobanu V; Zălaru MC; Steinbruh L; Pambuccian G; Popescu C
Med Interna (Bucur); 1973 Mar; 25(3):285-305. PubMed ID: 4136127
[No Abstract] [Full Text] [Related]
34. Dipyrone metabolism in liver disease.
Zylber-Katz E; Caraco Y; Granit L; Levy M
Clin Pharmacol Ther; 1995 Aug; 58(2):198-209. PubMed ID: 7648770
[TBL] [Abstract][Full Text] [Related]
35. Urinary sodium balance in patients with cirrhosis: relationship to quantitative parameters of liver function.
Wensing G; Lotterer E; Link I; Hahn EG; Fleig WE
Hepatology; 1997 Nov; 26(5):1149-55. PubMed ID: 9362355
[TBL] [Abstract][Full Text] [Related]
36. Hepatocyte growth factor and acute phase proteins in patients with chronic liver diseases.
Shiota G; Umeki K; Okano J; Kawasaki H
J Med; 1995; 26(5-6):295-308. PubMed ID: 8721905
[TBL] [Abstract][Full Text] [Related]
37. Effect of corticosteroid treatment on bilirubin metabolism in chronic aggressive hepatitis.
Kawasaki H; Ogata T; Irisa T; Hirayama C
Acta Hepatogastroenterol (Stuttg); 1977 Jun; 24(3):175-81. PubMed ID: 883466
[TBL] [Abstract][Full Text] [Related]
38. The effect of liver disease in man on the disposition of phenobarbital.
Alvin J; McHorse T; Hoyumpa A; Bush MT; Schenker S
J Pharmacol Exp Ther; 1975 Jan; 192(1):224-35. PubMed ID: 235636
[TBL] [Abstract][Full Text] [Related]
39. Heparin response and clearance in acute and chronic liver disease.
Sette H; Hughes RD; Langley PG; Gimson AE; Williams R
Thromb Haemost; 1985 Oct; 54(3):591-4. PubMed ID: 4089794
[TBL] [Abstract][Full Text] [Related]
40. Plasma antithrombin III, alpha 2-plasmin inhibitor and plasminogen activities in cases of various liver diseases.
Ito K; Niwa M; Kawada T; Tanaka Y
Tokai J Exp Clin Med; 1986 Nov; 11(5):345-52. PubMed ID: 3672563
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
